Premium
Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum
Author(s) -
Cheng Weimin,
Chan Kwok Hung,
Chen Honglin,
Luo Ruixian,
Ng S. Park,
Luk Winsie,
Zheng Bojian,
Ji Mingfang,
Liang Jinsheng,
Sham Jonathan S.T.,
Wang DeKun,
Zong Yongsheng,
Ng Mun Hon
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.1641
Subject(s) - nasopharyngeal carcinoma , antibody , medicine , odds ratio , population , cancer , immunology , antigen , incidence (geometry) , carcinoma , oncology , physics , environmental health , optics , radiation therapy
We have evaluated the performance of 3 new EBV ELISA for the diagnosis of nasopharyngeal carcinoma (NPC). The tests were specific for EBNA 1 IgA, EBNA 1 IgG and zta IgG, respectively. Their distinct antigenic specificity permits these assays to be used in concert in an approach that differentiates patients and apparently healthy subjects on the basis of their antibody spectrum. By so exploiting a distinguishing feature of NPC first described by the late Werner Henle that the patients sustain high levels of a broad spectrum of serum EBV antibodies, this approach achieved a sensitivity of 92% and a specificity of 93%, surpassing the performance of each of these assays individually. The enhanced performance is especially useful in population screening. It was shown that relative risk of NPC sustained by apparently healthy subjects residing in a high incidence area for NPC in the Pearl River estuary in Southern China may vary according to EBV antibody spectrum. The risk of the cancer was markedly reduced with odds ratios of 0.009 for 59% of those who had low level of all 3 antibodies. The risk was increased as antibody spectrum broadens and the risk was the highest with an odds ratio of 138 for 0.4% of those who had high levels of all 3 antibodies. Thus, EBV antibody spectrum may serve to guide follow‐up measures for early detection of the cancer and/or risk counseling according to level of the risk of the cancer sustained by the screened individuals. © 2001 Wiley‐Liss, Inc.